You must have javascript enabled on your browser to get the best out of this website and to request reports.

If you are unsure how to enable javascript in your browser, please consult the Help menu in your browser. This website may also be able to show you how to enable javascript:

Molecular Pathology approach to cancer : 9 - 11 May 2016

Download and share
with colleagues

A4 promotional leaflet


The European Association for Cancer Research (EACR) and the Organisation of European Cancer Institutes (OECI) are jointly organising the sixth edition of this course on the Molecular Pathology Approach to Cancer, to be held in Amsterdam from 09 – 11 May 2016.

Target audience
The course focuses on novel concepts in molecular pathology of human solid cancers and on the practical application of molecular tests in pathology. This course will provide knowledge beneficial for practising pathologists and oncologists, residents and fellows in pathology and oncology, and molecular biologists with interest in diagnostic and molecular pathology.


Genomic analyses of human cancers are leading to the identification of the genetic determinants of cancer development, progression and response to targeted therapies. Treatment decisions selecting therapies for cancer patients can no longer be solely based on histopathological analyses of tumours. In fact, molecular tests are rapidly being incorporated into routine clinical practice. The role of pathologists in the implementation of molecular tests in diagnostic practice and the ability of pathology laboratories to perform these tests in an optimal manner are crucial for the successful translation of scientific advancements into useful biomarkers. In addition, a multidisciplinary approach for the delivery of optimal molecular characterization of cancers is essential for the realization of the promises of precision medicine.

99% of the participants from 2015 would recommend the course to others

"Thanks a lot for the excellent meeting, both in terms of quality of the lectures, good organisation and nice atmosphere, very friendly and international. I’ve learned so much and enjoyed the attendance! This training course has been certainly very worthwhile and I’ll highly recommend it to my colleagues."

"Attending the course was a wonderful experience. It gave me the opportunity to attend talks given by international scientists, which allowed me to improve my knowledge and to have an overview on different aspects and methods of cancer research."

"The organisation of the course was perfect and the speakers were very open to discussions and questions asked by the participants."

Topics to be covered
This course will provide an up-to-date review of the state-of-the-art of molecular pathology of solid malignancies, current molecular biomarkers and the challenges for their assessment and interpretation in the context of different types of solid tumour. Conceptual and practical advancements in the development of novel biomarkers for cancer patients will also be discussed.

The topics that will be covered in the course include:

  • The role of pathologists in precision medicine
  • Massively parallel sequencing
  • Perspectives of molecular testing for clinical decision-making in Europe and North America
  • Causes of possible pitfalls in molecular analysis
  • Molecular pathology of breast cancers and the incorporation of novel molecular tests into clinical practice
  • Novel findings in ovarian and endometrial cancers
  • Targeted therapy in melanoma
  • KIT and novel targets in gastrointestinal stromal tumours
  • Genetic testing in colorectal and lung cancers
  • Translocations in sarcomas and central nervous system tumours

We hope that you will be able to join us for this innovative course.

Scientific organising committee

Richard Marais

Jorge Reis-Filho

Giorgio Stanta

Marc van de Vijver


CME Accreditation

CME Accreditation from UEMS-EACCME and the Accreditation Council of Oncology in Europe is being applied for. CME Accreditation recognises the high quality of a meeting from an educational and scientific perspective.